Stanford researchers have created the orthoCD3 T cells, by engineering T cells to resist depletion from anti-CD3 antibodies during lymphodepletion, thereby, enhancing the efficacy of T cell therapies for cancer, autoimmune disorders, and transplant rejection.
Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.
Stanford researchers have developed a novel mutant IL-9 receptor (IL9R) that significantly enhances the in vivo engraftment, expansion, and anti-tumor activity of adoptively transferred T cells.
Stanford researchers have developed a modular system of Synthetic cytokine receptors (SCRs), which are customizable receptors that mimic cytokine signals to precisely control immune cell behavior without the need for external cytokines.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a non-viral, homology-independent method for precise targeted DNA insertions into T-cells using electroporation and CRISPR/Cas9, enabling cost-effective production of CAR T-cells for T-cell therapies.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
Researchers at Stanford, led by Prof. Crystal Mackall and Prof. Jennifer R Cochran, have developed a unique approach to cancer treatment by tackling both the innate and adaptive immune systems.